Skip to main content

Fitch shows lack of derivatives disclosure

LONDON -- Fitch Ratings' recent study of hedge accounting and disclosure among corporates has revealed a somewhat surprising lack of public disclosure of derivatives use. The study focused mainly on US corporates that have been reporting under FAS 133 -- the accounting rule that should have improved the transparency of derivatives use. And because of this lack of transparency, Fitch is concerned about potential reporting and restatement risk caused by difficulties associated with hedge accounting.

"The surprising thing to us was that even though these companies had been reporting under FAS 133 there really isn't enough public disclosure to serve as a basis for decent credit analysis," says Bridget Gandy, managing director at Fitch in London and co-author of the report. "To see that there really isn't that much useful reporting from corporates using FAS 133 is quite surprising."

Fitch

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Want to know what’s included in our free membership? Click here

Show password
Hide password

Emerging trends in op risk

Karen Man, partner and member of the global financial institutions leadership team at Baker McKenzie, discusses emerging op risks in the wake of the Covid‑19 pandemic, a rise in cyber attacks, concerns around conduct and culture, and the complexities of…

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here